Iambic Therapeutics Inc. presented preclinical data on IAM-1363, a selective and irreversible HER2 and pan-HER2 mutant inhibitor in HER2-driven NSCLC models. In vitro studies across a panel of HER2-altered NSCLC cell lines demonstrated that IAM-1363 exhibits potent antiproliferative activity in both HER2-amplified and HER2-mutant models.
A panel at Biocom California’s 15th Annual Global Life Science Partnering & Investor Conference covered the emerging use of artificial intelligence (AI) to discover and develop drugs. “We’re in a very different place than we were five years ago, or even three years ago, even two years ago, from our ability to harness AI to make advances,” Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics Inc., told the audience, adding that the development is actually accelerating.
H. Lundbeck A/S and Iambic Therapeutics Inc. have entered into a strategic research collaboration focused on the discovery of a small-molecule therapeutic for the treatment of migraine. The collaboration will leverage Iambic’s artificial intelligence (AI)-powered drug discovery platform.
Iambic Therapeutics Inc. has described HER2 (erbB2) and HER2 (exon 20 insertion [Ex20Ins] [Ala775_Gly776insTyrValMetAla]) mutant inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).
Iambic Therapeutics Inc. has disclosed quinazoline compounds acting as cyclin-dependent kinase (CDK) inhibitors, particularly CDK2 and/or CDK4 and/or CDK6 inhibitors reported to be useful for the treatment of ovarian and breast cancer.
Iambic Therapeutics Inc. (formerly Entos Inc.) has closed a $100 million series B financing. The company intends to use this funding to support continued artificial intelligence (AI) platform innovations and advance candidates into clinical development.
